- Home
- HLP vs WHWK Comparison
HLP vs WHWK Comparison
Compare HLP & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HLP | WHWK |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.1M | 95.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | HLP | WHWK |
|---|---|---|
| Price | $1.47 | $2.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 88.4K | ★ 193.7K |
| Earning Date | 05-15-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $16,731,357.00 | $14,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $69.15 | ★ N/A |
| Revenue Growth | ★ 19.13 | N/A |
| 52 Week Low | $0.61 | $1.39 |
| 52 Week High | $1.82 | $3.81 |
Technical Indicators
Market Signals| Indicator | HLP | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 59.62 |
| Support Level | $1.48 | $2.10 |
| Resistance Level | $1.65 | $2.36 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 14.26 | 83.87 |
Price Performance
Historical ComparisonAbout HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.